Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. 10x Genomics, Inc. is one of the seven stocks on our list of most promising stocks.

On December 15, 2025, Barclays analyst Luke Sergott raised the price target for TXG from $17 to $22 while maintaining an Overweight rating, reflecting confidence in the company’s positioning in life sciences tools and expectations of stabilizing end‑market demand. Barclays cited improving conditions for research funding and the tools sector as part of its positive outlook.

In contrast, on December 11, 2025, Citigroup downgraded 10x Genomics, Inc. (NASDAQ:TXG) from Buy to Neutral with an $18 price target, highlighting uncertainty about capital expenditures in academic and biopharma research that could weigh on instrument sales recovery.

These differing assessments are grounded in the recent operational context. For the full‑year 2024, 10x Genomics, Inc. (NASDAQ:TXG) reported revenue of approximately $610.8 million, a slight year‑over‑year decline, reflecting soft demand in some core research segments. Analyst caution also stems from guidance for 2025 that implies modest growth, with revenue expected to be roughly flat given continued funding uncertainty in key markets.

10x Genomics, Inc. (NASDAQ:TXG) is a biotechnology company that develops advanced tools for high‑resolution genomic analysis, especially single‑cell and spatial biology technologies. It is not a traditional gene‑editing therapeutic developer (e.g., it does not create CRISPR‑based drugs), but its platforms are widely used to analyze the effects of gene editing in cells and tissues.

While we acknowledge the potential of TXG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW  Disclosure: None.